KPRX
|Kiora Pharmaceuticals Inc
NASDAQ
USD 3.02
+0.08|+2.72%
Current Price
USD 3.02
Change
+USD 0.08 (2.72%)
P/E Ratio
Dividend Yield
Market Cap
9.38M
Volume
121,624
Open
USD 2.92
Previous Close
USD 2.94
52-Week High
USD 5.55
52-Week Low
USD 2.51
About Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydr...
Sector:Healthcare
Industry:Biotechnology
CEO:Dr. Brian M. Strem Ph.D.
Employees:12
Headquarters:Encinitas, USA
Website:www.kiorapharma.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions